Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00640250
Other study ID # Mekos 07 2P3.2 201
Secondary ID 2007-007130-19WI
Status Completed
Phase Phase 2
First received March 3, 2008
Last updated April 6, 2018
Start date April 2008
Est. completion date September 2009

Study information

Verified date April 2018
Source Allerderm
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact dermatitis and a positive patch test (current or previous) to the corresponding reference petrolatum allergen ("sensitives").


Description:

Primary endpoint:

To evaluate the diagnostic performance of Disperse blue 106 and Bronopol T.R.U.E. Test allergens in 20 adult subjects per allergen with a clinical history of contact dermatitis and a positive patch test to the respective reference allergen. Evaluations will include:

- Determination of the lowest concentration eliciting positive skin reactions (+1 or +2) in 70-90% of sensitive subjects.

- Frequency of positive, negative, doubtful and irritant reactions for each allergen and tested concentration.

- Concordance/discordance as compared to the corresponding reference petrolatum allergen.

Secondary endpoint:

To evaluate the safety of Disperse blue 106 and Bronopol T.R.U.E. Test allergens in 20 adult subjects per allergen with a clinical history of contact dermatitis and a positive patch test to the respective reference allergen. Evaluations will include:

- The frequency of tape-induced irritation at the test site, incomplete panel adhesion, and subject-reported sensations of itching or burning.

- The frequency and characterization of adverse events and serious adverse events.

- The frequency and characterization of late and/or persistent reactions.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date September 2009
Est. primary completion date March 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Current or previous symptoms and/or history consistent with allergic contact dermatitis, and positive patch test (within the past 5 years) to Bronopol OR Current or previous symptoms and/or history consistent with allergic contact dermatitis, and a positive patch test (within the past 5 years) to Disperse blue 106 or Disperse blue 106/124 allergen mix.

- All subjects must be adults (18 years of age or older) and otherwise in good health.

- Premenopausal female subjects must consent to a urine pregnancy test; results must be negative for study inclusion.

- Informed consent must be signed and understood by each subject, and consistent with all institutional, local and national regulations.

Exclusion Criteria:

- Subjects unable to meet inclusion requirements.

- Women who are breastfeeding or pregnant.

- Topical treatment during the last 7 days with corticosteroids or other immunosuppressive agents on or near the test area.

- Systemic treatment during the last 7 days with corticosteroids (equivalent to > 10 mg prednisone) or other immunosuppressive agents.

- Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks.

- Acute dermatitis outbreak or dermatitis on or near the test area on the back.

- Subjects unable to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting test panels from excess moisture due to showering or vigorous activity).

- Subject participation in clinical trials of investigational drugs, treatments or devices other than T.R.U.E. Test during this study or 3 weeks prior to inclusion in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2 Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.

Locations

Country Name City State
Denmark Odense University Hospital Odense C
United States Dermatology Specialists PSC Louisville Kentucky

Sponsors (1)

Lead Sponsor Collaborator
Allerderm

Countries where clinical trial is conducted

United States,  Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic Performance: Optimal Test Allergen Concentration Lowest concentration eliciting 1+ or 2+ positive reactions in 70-90% of subjects Visits 3-5: 3-21 days after application
Primary Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration Percentage (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 3- all subjects Visit 3: 3 days after application
Primary Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration Percent (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 4- all subjects Visit 4: 7 days after application
Primary Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 3- all subjects Visit 3: 3 days after application
Primary Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 4- all subjects Visit 4: 7 days after application
Primary Concordance Between Investigational Allergen and Reference Allergen Concordance between disperse blue or bronopol and the respective reference petrolatum allergen Visit 5: 21 days after patch application
Secondary Frequency of Irritation (Tape Reactions), Late/Persistent Reactions and Subject-reported Itching or Burning Percentage of subjects who exhibited irritation and itching or burning at patch removal (entire panel is evaluated) and late/persistent reactions.
Late reactions occur 7-10 days after patch application Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application
Day 2-21
Secondary Adverse Events The adverse event-reporting period began at application and ended with the Day 21 visit. Adverse events were followed until they resolved. Serious adverse events and those assessed by the investigator as possibly related to the investigational product were to be followed until they resolved or until the investigator assessed them as chronic or stable. Days 0-21
See also
  Status Clinical Trial Phase
Completed NCT00371163 - Molecular and Cellular Characterization of Spongiotic Dermatitis N/A
Completed NCT02028208 - Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study Phase 2
Not yet recruiting NCT04853823 - A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB Phase 1
Recruiting NCT06387472 - DermAI to Evaluate Human Factor of Testing N/A
Completed NCT02700373 - A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers Phase 1
Completed NCT03089775 - Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis Phase 1
Completed NCT04438135 - Children With Aluminium Contact Allergy: Cutaneous Exposure Study N/A
Recruiting NCT06189144 - Testing an Intervention in Irritative Contact Dermatitis N/A
Completed NCT04921163 - Children With Aluminium Contact Allergy: Oral Exposure Study N/A
Not yet recruiting NCT02026700 - Bariederm Cream in Chronic Contact Dermatitis N/A
Completed NCT02028182 - Clinical Evaluation of Lyral® Dose Response Study Phase 2
Completed NCT00824889 - Exploratory Study of Natural Killer Cells in Human Skin N/A
Completed NCT00646867 - Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis N/A
Withdrawn NCT01518348 - Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents Phase 3
Recruiting NCT03705182 - Prevention of Dermatitis in Epoxy Exposed Workers N/A
Terminated NCT03198390 - Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions
Completed NCT00614289 - Novel Topical Treatment of Hand Dermatitis (Eczema) Phase 1
Recruiting NCT06331390 - Assessment of Niacinamide Cosmetic Product Efficacy in Model of Irritant Contact Dermatitis N/A
Completed NCT00640614 - Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy Phase 3
Recruiting NCT06177314 - Molecular Diagnosis of Allergic Contact Dermatitis